Advances in anticoagulant therapy for cirrhosis combined with atrial fibrillation.
10.3760/cma.j.cn501113-20230310-00104
- Author:
Jie Ya REN
1
;
Xin Ting LI
1
;
Min Cong LONG
1
;
Hui LIU
1
;
Nu Er TANG
1
;
Rong Jiong ZHENG
1
;
Xiao Bo LU
1
Author Information
1. Center for Infection-Liver Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China.
- Publication Type:Journal Article
- Keywords:
Anticoagulant therapy;
Atrial fibrillation;
Liver cirrhosis
- MeSH:
Humans;
Atrial Fibrillation/epidemiology*;
Stroke/epidemiology*;
Anticoagulants/therapeutic use*;
Hemorrhage;
Liver Cirrhosis/drug therapy*;
Risk Factors
- From:
Chinese Journal of Hepatology
2023;31(5):551-555
- CountryChina
- Language:Chinese
-
Abstract:
Relevant research in recent years has demonstrated that the atrial fibrillation occurrence rate is significantly higher in patients with cirrhosis. The most common indication for long-term anticoagulant therapy is chronic atrial fibrillation. The use of anticoagulant therapy greatly reduces the incidence rate of ischemic stroke. Patients with cirrhosis combined with atrial fibrillation have an elevated risk of bleeding and embolism during anticoagulant therapy due to cirrhotic coagulopathy. At the same time, the liver of such patients will go through varying levels of metabolism and elimination while consuming currently approved anticoagulant drugs, thereby increasing the complexity of anticoagulant therapy. This article summarizes the clinical studies on the risks and benefits of anticoagulant therapy in order to provide a reference for patients with cirrhosis combined with atrial fibrillation.
